苯并[b]噻吩-3-乙酰氯 | 100068-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 苯并[b]噻吩-3-乙酰氯
• 英文名称: benzo[b]thiophene-3-acetyl chloride
• 英文别名: 2-(1-Benzothiophen-3-yl)acetyl chloride
• CAS: 100068-20-0
• 化学式: C₁₀H₇ClOS
• 分子量: 210.684
• InChiKey: HRWDABYNJCKFQD-UHFFFAOYSA-N

物化性质

• 沸点：
  335.6±25.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯并[b]噻吩-3-乙酰氯 在 三乙胺 作用下， 以 乙醚 、 丙酮 为溶剂， 生成 3-(benzo[b]thiophen-3-yl)-2-oxopropyl acetate
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p
• 作为产物：
  描述：

  苯并[b]噻吩-3-乙酸 在 氯化亚砜 作用下， 反应 3.0h， 生成 苯并[b]噻吩-3-乙酰氯
  参考文献：
  名称：

  酰胺酸的分子内环化成吡咯烷二硫代（或[1]苯并噻吩并）[3]氮杂二酮

  摘要：

  吡咯烷酮[2,1- b ]噻吩并[3,2（2,3）-f ] [3]氮杂二酮7a，b和吡咯烷酮[ 2,1 - b ]-[1]苯并噻吩并[3,2（描述了从噻吩或[1]苯并噻吩-苯乙酸开始的2，3）-f ] [3]氮杂二酮7c，d。它们使用三乙基硅烷的选择性还原得到相应的a庚酮17a-d。

  DOI：

  10.1002/jhet.5570340134

文献信息

• Methods and compositions for selectin inhibition
  申请人：Kaila Neelu

  公开号：US20050101569A1

  公开（公告）日：2005-05-12

  The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.

  本发明涉及抗炎物质领域，更特别地涉及作为哺乳动物粘附蛋白拮抗剂的新化合物。在某些实施例中，提供了治疗选择素介导疾病的方法，包括给予式I的化合物： 其中组分变量在此定义。
• Methods and Compositions for Treatment of Scleritis and Related Disorders
  申请人：Bedard Patricia W.

  公开号：US20080125454A1

  公开（公告）日：2008-05-29

  The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W 1 , W 2 , R 1 , L, X, Y, Z, and n 1 are defined as described herein.

  目前的教导涉及抗炎物质领域，更具体地涉及对用于治疗巩膜炎、巩膜炎症状或与巩膜炎相关疾病有用的化合物。在一个方面，治疗巩膜炎、巩膜炎症状或巩膜炎相关疾病的方法通常包括向受试者施用公式I的化合物： 或其药用可接受的盐、水合物或酯，其中W 1 ，W 2 ，R 1 ，L，X，Y，Z和n 1 的定义如本文所述。
• 3-(Arylacetylamino)-<i>N</i>-methylbenzamides:  A Novel Class of Selective Anti-<i>Helicobacter pylori</i> Agents
  作者：Ryoichi Ando、Makoto Kawamura、Noriko Chiba

  DOI：10.1021/jm010307o

  日期：2001.12.1

  preceded by the random screening of our chemical library, a novel class of selective anti-Helicobacter pylori agents was generated. Consequently, the 3-(arylacetylamino)-N-methylbenzamides, which were quite easy to prepare, showed potent inhibitory activity against Helicobacter pylori but exhibited no inhibitory activity against other sorts of bacteria and fungi, e.g., Staphylococcus aureus, Bacillus subtilis

  经过化学修饰并随机筛选我们的化学文库后，产生了新型的选择性抗幽门螺杆菌药物。因此，很容易制备的3-（芳基乙酰氨基）-N-甲基苯甲酰胺显示出对幽门螺杆菌的有效抑制活性，而对其他种类的细菌和真菌，例如金黄色葡萄球菌，枯草芽孢杆菌，大肠杆菌等则没有抑制活性。 ，铜绿假单胞菌，脆弱拟杆菌和白色念珠菌。这些化合物显示出有效的抗-H。在酸性条件下的幽门螺杆菌活性，而阿莫西林和克拉霉素则降低活性。3-（3-芳基丙酰氨基）-N-甲基苯甲酰胺，3-（芳氧基乙酰基氨基）-N-甲基苯甲酰胺和（3-甲基氨基甲酰基苯基）氨基甲酸1-芳基甲基酯也显示出有效的抗-H。幽门螺杆菌活动。最后，我们选择7n（BAS-118）作为候选化合物进行进一步评估。
• Highly selective .kappa.-opioid analgesics. 2. Synthesis and structure activity relationships of novel N-(2-aminocyclohexyl)arylacetamide derivatives
  作者：Paul R. Halfpenny、Raymond G. Hill、David C. Horwell、John Hughes、John C. Hunter、Stephen Johnson、David C. Rees

  DOI：10.1021/jm00127a036

  日期：1989.7

  chemical synthesis and the development of structure-activity relationships (SAR) for the kappa opioid receptor affinity and mu/kappa opioid receptor selectivity of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives. The SAR of this series are investigated by consideration of structural modifications made to the aromatic moiety, the amide linkage, and cyclohexane and the pyrrolidine ring substituents

  本文描述了新型N-[（2-氨基环己基）芳基]乙酰胺衍生物的κ阿片受体亲和力和mu / k阿片受体选择性的化学合成和结构-活性关系（SAR）的发展。通过考虑对原型kappa选择性激动剂PD117302（反式-N-甲基-N- [2-（ 1-吡咯烷基）环己基]苯并[b]噻吩-4-乙酰胺）（1）。报道了23种新化合物的Kappa和mu阿片受体结合亲和力。观察到，通过C-4位连接的苯并[b]噻吩芳族系统获得了最佳的mu / kappa受体选择性，根据空间和电子参数进行讨论。酰胺键已被反向酰胺，酯，氨基亚甲基，硫代酰胺和仲酰胺取代。这些等排物中最好的是N-甲基酰胺。与未取代的化合物，例如化合物14，反式-（+/-）-N-甲基-N- [2- []相比，PD117302的吡咯烷环在3-位被羟基亚甲基取代提高了mu /κ选择性。 3-（羟甲基）-1-吡咯烷基]环己基] -4-苯并[b]呋喃乙酰胺单盐酸盐，mu
• [EN] ANTIDIABETIC AGENTS<br/>[FR] AGENTS ANTIDIABETIQUES
  申请人：MERCK & CO., INC.

  公开号：WO1999051225A1

  公开（公告）日：1999-10-14

  (EN) Compounds of formula (I) as well as tautomers, pharmaceutically acceptable salts, hydrates, prodrugs and reduced forms are disclosed. The compounds are useful for the treatment and prevention of diabetes mellitus, and in particular, for the treatment or prevention of hyperglycemia in diabetic patients.(FR) L'invention concerne des composés de formule (I), ainsi que des tautomères, des sels pharmaceutiquement acceptables, des hydrates, des promédicaments, et des formes réduites de ces composés. Les composés de cette invention peuvent être utilisés pour traiter et prévenir le diabète sucré, et plus particulièrement pour traiter et prévenir l'hyperglycémie chez les patients diabétiques.

  化合物的公式（I）以及其异构体、药学上可接受的盐、水合物、前药和还原形式被揭示。这些化合物可用于治疗和预防糖尿病，特别是用于治疗或预防糖尿病患者的高血糖。